Related Experiment Video
Updated: Aug 18, 2026

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence
1Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland. nfpopik@cyf-kr.edu.pl
Abstract:
The ability of memantine (1-amino-3,5-dimethyl-adamantane) to block the expression and maintenance of morphine dependence was examined in mice. When administered to morphine-dependent mice 45 min prior to naloxone challenge, memantine (7.5-30 mg/kg IP) in a dose-dependent manner reduced jumping behavior (a manifestation of the expression of dependence). The ability of memantine to attenuate naloxone-precipitated jumping was reversed by administration of glycine, an observation consistent with electrophysiological studies indicating that memantine is a use-dependent (uncompetitive) N-methyl-D-aspartate (NMDA) antagonist. In an independent series of experiments, the effect of memantine on a preestablished morphine dependence was investigated. A residual dependence to morphine was present 3 days after cessation of morphine administration. Repeated administration of memantine (10 mg/kg, IP) or the competitive NMDA antagonist NPC 17742 [2R, 4R, 5S-(2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid)] (6 mg/kg, IP) during this 3-day period abolished subsequent naloxone-precipitated jumping. In contrast, when administered concurrently with morphine after dependence had already been well established, memantine (10 and 20 mg/kg, IP) did not affect the maintenance of morphine dependence. Based on these finding, NMDA antagonists appear to inhibit the maintenance of opioid dependence, an action distinct from their acute inhibitory effects on the expression of dependence. Nonetheless, these regimen-dependent effects of memantine indicate that the most efficacious use of NMDA antagonists would be in detoxified subjects, rather than in individuals with an established dependence who are currently abusing opioids.
Insights
Memantine, an N-methyl-D-aspartate (NMDA) antagonist, can block the expression and maintenance of morphine dependence in mice. Its efficacy is greatest in detoxified subjects, not those with established opioid dependence.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Research
Background:
- Opioid dependence is a significant public health concern.
- N-methyl-D-aspartate (NMDA) receptors play a role in addiction.
- Memantine is an NMDA receptor antagonist.
Purpose of the Study:
- To investigate the efficacy of memantine in blocking the expression and maintenance of morphine dependence in a mouse model.
- To differentiate the effects of memantine on the acute expression versus the established maintenance of opioid dependence.
Main Methods:
- Morphine-dependent mice were challenged with naloxone to precipitate withdrawal symptoms (jumping behavior).
- Memantine was administered before naloxone challenge to assess its effect on dependence expression.
- Memantine was administered repeatedly during a withdrawal period to assess its effect on dependence maintenance.
- The effects of memantine were compared to a competitive NMDA antagonist (NPC 17742) and glycine.
Main Results:
- Memantine dose-dependently reduced naloxone-precipitated jumping, indicating it blocks the expression of morphine dependence.
- The effect of memantine on dependence expression was reversed by glycine, supporting its role as an NMDA antagonist.
- Repeated memantine administration during a 3-day withdrawal period abolished subsequent naloxone-precipitated jumping, suggesting it inhibits dependence maintenance.
- Memantine did not affect the maintenance of established morphine dependence when administered concurrently with morphine.
Conclusions:
- NMDA antagonists, like memantine, can inhibit the maintenance of opioid dependence, a distinct action from their acute effects on dependence expression.
- Regimen-dependent effects suggest NMDA antagonists are more efficacious for preventing or treating withdrawal in detoxified individuals rather than those actively dependent.
- These findings highlight the potential therapeutic utility of NMDA antagonists in opioid addiction treatment, particularly during the detoxification phase.
Related Concept Videos
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Depressants: Alcohol and Nicotine
Opioid Receptors: Overview
Analgesia and Pain Management
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioid Analgesics: Synthetic and Semisynthetic Opioids

